GOUTY ARTHRITIS PRESENTED BY, JISMI MATHEW LINCY K OUSEPH MEENUPRIYA OONNANAL SMITHA V CHACKO VINEETHA MARY MATHEW.

Slides:



Advertisements
Similar presentations
GOUT Disease caused by tissue deposition of Monosodium urate crystals as a result of supersatuaration of extra cellular fluid with MSU.
Advertisements

Team Meeting Presentations
Copyright © 2015 Cengage Learning® Chapter 15 Urinary System Drugs.
1. Describe the pathogenesis of hyperuricemia and gout Goup C1 Group C1.
Purine degradation & Gout (Musculoskeletal Block) Purine degradation pathway Fate of uric acid in humans Gout and hyperuricemia: Biochemistry Types Treatment.
{ Gout and Bursitis Asfand Baig.   Inflammatory arthritis associated with hyperuricaemia* and intra-articular sodium urate crystals Gout.
Purine Degradation & Gout (Musculoskeletal Block)
Prepared by : Tamara Odeh Diana Jawhari Supervised by : Dr. Ola Ayesh.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 74 Drug Therapy of Gout.
Gout.
 Gout is characterized by elevated uric acid concentrations in blood and urine due to variety of metabolic abnormalities that include overproduction.
DR. ABDULRAHMAN AL-AJLAN
Uric Acid Metabolism & Gout. Nucleic Acids Mononucleotide Base + Sugar + Phosphoric Acid Base: Purine or Pyrimidine Polynucleotide (DNA or RNA) Mononucleotides.
Purine degradation & Gout (Musculoskeletal Block).
Gout Dr. Wael H.Mansy, MD Assistant Professor College of Pharmacy King Saud University.
Familial metabolic disease Characterized by : Acute arthritis Uric stones in the kidneys Hyperuricemia.
GOUT. By Prof. Azza El- Medany Dr. Osama Yousf OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe.
Purine Degradation & Gout (Musculoskeletal Block)
Chapter 13 Agents Used to Treat Hyperuricemia and Gout.
Uric Acid Metabolism & Gout. Nucleic Acids Mononucleotide Base + Sugar + Phosphoric Acid Base: Purine or Pyrimidine Polynucleotide (DNA or RNA) Mononucleotides.
Gout By Shravya & Helen. Gout is… An inflammatory arthritis associated with hyperuricaemia and intra-articular sodium urate crystals.
GOUT. OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe treatment of acute gouty arthritis Describe.
Uric Acid Metabolism & Gout
GOUT. By Prof. Azza El- Medany Dr. Osama Yousf OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe.
Gout Familial metabolic disease characterized by : Acute arthritis Uric acid stones in the kidneys Hyperuricemia.
More than 100 different disorders
Nursing Management: Arthritis and Connective Tissue Diseases
GOUT.
Purine degradation & Gout (Musculoskeletal Block) Purine degradation pathway Fate of uric acid in humans Gout and hyperuricemia: Biochemistry Types Treatment.
Gout Gouty Arthritis By Mike Parenteau.
Clinical Case #6 By Chen, chun-Yu (Kim) Chen, I -chun (Afra) Chen, I -chun (Afra)
Four Stages of Gout  Asymptomatic hyperuricemia Elevated levels of uric acid in the blood but no other symptoms Does not require treatment  Acute gout/Acute.
CHAPTER © 2012 The McGraw-Hill Companies, Inc. All rights reserved. 20 Nonopioid Analgesics, Nonsteroidal Antiinflammatories, and Antigout Drugs.
Gout Familial metabolic disease characterized by : Acute arthritis Uric acid stones in the kidneys Hyperuricemia.
Agents Used to Treat Hyperuricemia and Gout
GOUT A metabolic disease in which tissue deposition of crystals of monosodium urate occurs from supersaturated extracellular fluids and results in one.
GOUT: DIAGNOSIS AND MANAGEMENT. Gout Metabolic disorder due to excessive accumulation of uric acid in tissues leading to acute and chronic arthritis and.
Drug Therapy of Gout. Drug therapy of gout What Is Gout?
Metabolic Diseases of the Bone
Dr. Müge Bıçakçıgil Kalaycı
StagesClinical Features (1)Asymptomatic hyperuricemiahigh uric acid level is present but without symptoms (2) Acute Gouty Arthritishigh uric acid level.
Anna Pardue NS Methodist University.  As we known “Rich man’s disease.”  Inflammatory arthritis, a metabolic disorder that causes the deposition of.
GOUTY ARTHRITIS PRESENTED BY, JISMI MATHEW LINCY K OUSEPH MEENUPRIYA OONNANAL SMITHA V CHACKO VINEETHA MARY MATHEW.
Gout Pharmacotherapies Joseph Kitzmiller MD PhD FCP 5086 Graves Hall Assistant Professor – Biological Chemistry & Pharmacology
ANTI-GOUT DRUGS. GOUT A familial metabolic disease characterized by recurrent episodes of acute arthritis due to deposits of monosodium urate in joints.
Drugs in gout epidemiology Male to female ration 10:1 Prevalence of hyperuricemia 5% Prevalence of gout 0.2%
Purine Degradation & Gout (Musculoskeletal Block) Purine degradation pathway Fate of uric acid in humans Gout and hyperuricemia: Biochemistry Types Treatment.
Gout Ashley Guzman Primary Care I: Acute and Chronic Health Problems
GOUT GOUT.
Crystalopathies Joanna Zalewska.
CHAPTER 33 Drugs affecting muscles and joints
Gout Is recurrent inflammatory disorder characterized by
Purine Degradation & Gout (Musculoskeletal Block)
Gout.
Drugs in gout epidemiology Prevalence of hyperuricemia 5%
Introduction to pathology
Drug Therapy of Gout 1.
GOUT.
Gout and Hyperuricaemia
RUINS IN POMPEI, ITALY. RUINS IN POMPEI, ITALY.
Antiuricaemic drugs Dr A.W Olusanya.
Mr. Smith, 51, came to the family doctor because of severe pain in his left knee. The patient gave the pain began suddenly at 2 am, woke him from his.
Gout By: Patience Alley, Albert Watson, and Hunter Kimball.
Gout and Hyperuricaemia
How to Find Relief & Reduce Flare-Ups
Purine Degradation & Gout (Musculoskeletal Block)
Drugs in gout epidemiology Prevalence of hyperuricemia 5%
Purine Degradation & Gout (Musculoskeletal Block)
Presentation transcript:

GOUTY ARTHRITIS PRESENTED BY, JISMI MATHEW LINCY K OUSEPH MEENUPRIYA OONNANAL SMITHA V CHACKO VINEETHA MARY MATHEW

INTRODUCTION

DEFINITION SYNDROME OF ACUTE ATTACKS OF ARTHRITIS CAUSED BY HYPERURICAEMIA. (Brown & Edwards, 2009)

CAUSES INCREASE URIC ACID PRODUCTION UNDER- EXCRETION OF URIC ACID BY THE KIDNEYS INCREASED INTAKE OF FOODS CONTAINING PURINES

TYPES OF GOUT PRIMARY GOUT SECONDARY GOUT

AETIOLOGY (Brown & Edwards, 2009) ACIDOSIS OR KETOSIS ALCOHOLISM DIABETES MELLITUS HYPERTENSION OBESITY OR STARVATION RENAL DISEASE SICKLE CELL ANAEMIA USE OF CERTAIN COMMON DRUGS MALIGNANT DISEASE

PATHOPHYSIOLOGY(Lehne, 2009) INCREASED PURINE SYNTHESIS DECREASED RENAL EXCRETION HYPERURICAEMIA CRYSTALLIZATION OF SODIUM URATE IN THE SYNOVIAL SPACE INFLAMMATION

CASE STUDY

PERSONAL DETAILS 57 YEAR OLD MAN RECENT IMMIGRANT FROM A FOREIGN COUNTRY

PAST HISTORY REPEATED ATTACKS OF JOINT PAIN

PRESENT HISTORY INCREASE IN SIZE OF A NODULE ON HIS ELBOW

CLINICAL MANIFESTATIONS GOUT CLIENT JOINT PAIN AFFECTED JOINTS; CLUSKY, CYANOTIC AND TENDER INFLAMMATION OF THE GREAT TOE DEPOSITS OF SODIUM URATE CRYSTALS CALLED TOPHI PRESENT ABSENT PRESENT

PHYSICAL EXAMINATION ARTHRITIS ON BOTH HANDS. TENDER AND RUBBERY SUBCUTANEOUS NODULE OVER THE ELBOW. SUBCUTANEOUS NODULE AT THE LEFT METATARSAL – PHALENGEAL JOINT AND LEFT METACARPAL – PHALENGEAL JOINT.

DIAGNOSTIC TESTS SERUM ACID LEVELS 24 HOUR URINE SPECIMEN SYNOVIAL FLUID ASPIRATION JOINT ASPIRATION X - RAY

X – RAY FINDINGS CLASSIC ‘ PUNCHED OUT ‘ LYTIC LESION AT DISTAL RIGHT FIRST METATARSAL. MARGINAL EROSIONS AND DECREASED JOINT SPACE AT META – CARPAL AND PHALENGEAL JOINTS. SUBCUTANEOUS NODULE (GOUTY TOPHUS ) AT FIRST METACARPAL – PHALENGEAL AND LEFT FIRST METATARSAL – PHALENGEAL JOINTS.

TREATMENT COLLABORATIVE CARE DRUG THERAPY NUTRITIONAL THERAPY

COLLABORATIVE CARE GOALS TERMINATION OF AN ACUTE ATTACK BY ANTI- INFLAMMATORY AGENTS PREVENTION OF FUTURE ATTACKS – USE OF ALLOPURINOL AVOIDANCE OF ALCOHOL AND FOOD HIGH IN PURINE PREVENTION OF COMPLICATIONS

COMPLICATIONS URIC ACID KIDNEY STONES HYPERTRIGLYCERIDAEMIA HYPERTENSION

COLLABORATIVE THERAPY JOINT IMMOBILISATION LOCAL APPLICATION OF HEAT OR COLD JOINT ASPIRATION INTRA – ARTICULAR CORTICOSTEROIDS

DRUG THERAPY NON – STEROIDAL AND ANTI – INFLAMMATORY DRUGS COLCHINE PROBENECID ALLOPURINOL

COLCHICINE

ACTION ANTI – INFLAMMATORY AGENT

SIDE EFFECTS NAUSEA ABDOMINAL PAIN VOMITING GI TOXICITY

CONTRA - INDICATIONS PREGNANCY CARDIAC, RENAL AND GI DISEASES

NURSING RESPONSIBILITIES WATCH FOR COMPLICATIONS; SEIZURES, BONE MARROW SUPPRESSION WATCH FOR GI TOXICITY

ALLOPURINOL

ACTION TREAT CHRONIC TOPHACEOUS GOUT PREVENT NEPHROPATHY

SIDE EFFECTS HYPERSENSTIVITY SYNDROME; RASH, FEVER, EOSINOPHILIA AND DYSFUNCTION OF THE LIVER AND KIDNEYS. GI REACTIONS NEUROLOGIC EFFECTS

CONTRA - INDICATION PREGENANCY

NURSING RESPONSIBILITY WATCH FOR ANY SIDE EFFECTS MONITOR SERUM URIC ACID LEVELS

PROBENECID

ACTION INHIBIT REABSORPTION OF URIC ACID

SIDE EFFECTS GI EFFECTS HYPERSENSTIVITY RECTIONS RENAL INJURY

CONTRA - INDICATIONS RENAL DISEASE PREGNANCY

NURSING MANAGEMENT WATCH FOR COMPLICATIONS AND SIDE EFFECTS.

NUTRITIONAL THERAPY WEIGHT REDUCTION PROGRAM DIETARY AVOIDANCE OF FOOD / FLUIDS WITH HIGH PURINE CONTENT eg; ANCHOVIES, LIVER, WINE, BEER ETC

NURSING MANAGEMENT NURSING INTERVENTION IMPLEMENTATION SUPPORTIVE CARE OF THE INFLAMED JOINTS AVOID CAUSING PAIN TO THE INFLAMMED JOINT HEALTH EDUCATION BED REST JOINT IMMOBILISATION USE OF BED CRADLES IMPORTANCE OF DRUG THERAPY AVOIDANCE OF PERCIPITATING FACTORS